Adjusted EBITDA was $ (0.8) million for the second quarter of fiscal 2026 compared to $1.3 million in the year ago period. The change primarily relates to the increased EXXUA launch investments and ...

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...

Get all latest & breaking news on Astellas Pharma. Watch videos, top stories and articles on Astellas Pharma at ...

Many individuals face challenges when swallowing whole tablets or capsules and often crush them or open the shells to make ...

Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA (gepirone) extended-r ...

AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...

This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are ...

Lenovo has teased its Legion Y700 refresh on Weibo, with leaks hinting at major spec upgrades and a possible March launch.

Ulanqab Kema’s growth is underpinned by a multifaceted strategic advantage. Its location in Ulanqab, Inner Mongolia, provides ...

The National Pharmaceutical Pricing Authority (NPPA) has fixed and notified the retail price of 37 new drugs in its recent meeting, under the provisions of the Drugs Prices Control Order (DPCO), 2013, ...

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Detailed price information for Aytu Biopharma Inc (AYTU-Q) from The Globe and Mail including charting and trades.